The impact of biosimilars in the U.S. will be gradual. Drug-company investors should still be wary.

Sections:  business   
Topics:  health   
RELATED ARTICLES
    BING NEWS:
    • Markus Pinter Joins RevoQuant AI as General Manager for Middle East and Africa
      RevoQuant AI, a leader in harnessing Big Data Analytics and Machine Learning Models to empower collaborative thinking within businesses, today announced a significant milestone with the appointment of ...
      04/18/2024 - 11:27 am | View Link
    • How A Decades-Old Medical Records Company Made A Huge AI Bet To Save Itself
      Veradigm's interim CEO Yin Ho has an audacious plan to reinvent what was formerly Allscripts with the $140 million acquisition of AI startup ScienceIO.
      04/17/2024 - 11:30 pm | View Link
    • Low-carb diets work. Why does the American Diabetes Association push insulin instead?
      The American Diabetes Association takes millions from companies that stand to profit from our reliance on drugs. Is that affecting their guidance?
      04/17/2024 - 7:24 am | View Link
    • Novartis: Innovating for the world, from India
      How Vasant 'Vas' Narasimhan is readying India to play a bigger role in its medicines pipeline as the company becomes a pure-play innovative firm ...
      04/16/2024 - 8:10 pm | View Link
    • What To Know About G42—The Emirati AI Giant That Just Got A $1.5 Billion Investment From Microsoft
      AI giant G42 is chaired by the powerful UAE royal Sheikh Tahnoon, backed by the UAE sovereign wealth fund and was heavily scrutinized over its ties to China.
      04/16/2024 - 12:11 am | View Link
    • More

     

    Welcome to Wopular!

    Welcome to Wopular

    Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

    Senh Duong (Founder)
    Wopular, MWB, RottenTomatoes

    Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

    MoviesWithButter : Our Sister Site

    More News